its been a buy ever since its been in the 15's range , its been a tough year for shareholders this year , but I think next year it will be a outperformer to the asx200
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025